English中文

Offstream
news


New England Journal of Medicine

A research study published in "The New England Journal of Medicine" describes a significant mortality response to the immunotherapy Atezolizumab used in conjunction with the chemotherapy nab-paclitaxel for a type of untreatable Breast cancer (Triple-negative) when the tumors also display programmed death ligand 1 (PD-L1) expression.

Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds

Sources:  The New England Journal of Medicine  The New York Times


Related